Slide 1: Investor Presentation January 2012
Investor Presentation January 2012
Slide 2: Safe Harbor
SAFE HARBOR Certain statements in this release concerning our future growth prospects are forward- looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements
Slide 3: Agenda
AGENDA BIOCON SNAPSHOT BRANDED FORMULATIONS STRATEGIC ALLIANCES RESEARCH & DEVELOPMENT FINANCIAL HIGHLIGHTS 3
Slide 4: Biocon Snapshot
BIOCON SNAPSHOT
Slide 5: Introduction
INTRODUCTION Biocon is an emerging, global Bio-pharmaceutical enterprise, focused on innovation to develop affordable products and services for patients, partners and healthcare systems across the world. Biocon is committed towards: Reducing therapy costs of chronic diseases. (diabetes, cancer & aut
Slide 6: Business Structure & Holdings
BUSINESS STRUCTURE & HOLDINGS Biocon Research , India | 100% R&D- Novel Molecules Biocon Biopharmaceuticals | 100% Mabs and Biosimilars ~61% | Promoters Biocon Sdn. Bhd, Malaysia | 100% PRODUCTS ~ 7 % | Employees & ESOP trust Biocon Overseas subsidiary ~32 % | Public Biocon SA, Switzerland | 100% Ov
Slide 7: A Portfolio Based Approach
A PORTFOLIO BASED APPROACH Insulins & Other Branded Research Novel Statins Immuno Biopharma Formulations Services Molecules Suppressants Portfolio Constituents Statins Simvastatin, Atorvastatin, Lovastatin, Rosuvastatin, Fluvastatin & Pravastatin Insulins & Insulin, Glargine & 2 Analogs (under devel
Slide 8: A Risk Balanced Growth Strategy
A RISK BALANCED GROWTH STRATEGY Small Molecules Research Biosimilars Services (Biologics & Growth Insulins) Verticals Novel Branded Molecules Formulations EMERGING EMERGINGMARKETS MARKETS FOCUS FOCUS 8
Slide 9: Research Services
RESEARCH SERVICES gS DISCOVERY SERVICES CLINICAL RESEARCH CLIENTS CLIENTS Large & mid-size Pharma & Biotech Companies On-going collaboration with over Syngene 60 companies worldwide Large & mid-size Pharma & Biotech Companies SERVICES Clinical Operations & Development Biology R&D Clinigene Clinical
Slide 10: Branded Formulations
BRANDED FORMULATIONS
Slide 11: Branded Formulations: Therapeutics Segments
BRANDED FORMULATIONS : THERAPEUTICS SEGMENTS 11
Slide 12: Branded Formulations: Products & Markets
BRANDED FORMULATIONS : PRODUCTS & MARKETS INDIA PRODUCT RANKINGS* Cardiology Myokinase 2 Oncotherapeutics BioMAb EGFR 2 Abraxane 3 Immunotherapy Tbis 2 Picon 2 * November MAT 2011 12
Slide 13: Biocon's Insulin Business (India)
BIOCON’S INSULIN BUSINESS (INDIA) MAT November 2011 YoY Biocon’s ranking Biocon’s market share by growth for value sales of 40 volume: IU insulin: #4 in overall insulin Market: 18% 40 IU Insulin: 11% #3 in the 40 IU Insulin market 36% Biocon: Glargine vials: 68% #1 in the Glargine vial market Novo N
Slide 14: Branded Formulations: INSUPen ease Launch
BRANDED FORMULATIONS : INSUPen® ease LAUNCH Designed for accuracy, efficiency, safety & economy. • Launched in October, 2011 • Based on proprietary German technology • Reusable delivery device capable of delivering both InsugenTM & BasalogTM • “One Call Does All” Support helpline Expected to add fur
Slide 15: Strategic Alliances
STRATEGIC ALLIANCES
Slide 16: Strategic Partnerships
STRATEGIC PARTNERSHIPS Discovery Commercialisation Research Services Amylin CIMAb IATRICa Vaccinex Optimer Mylan Pfizer BMS Diabetes Immunology Oncology Oncology First-in-class anti-infective Oncology, Auto-Ilmmune Diabetes Discovery to commercialisation NOVEL PEPTIDE BIOMAB EGFR, ITOLIZUMAB IMMUNOC
Slide 17: Biosimilars Commercialization Partnership: Pfizer
BIOSIMILARS COMMERCIALIZATION PARTNERSHIP: PFIZER Insulin and Insulin analogs Combines Biocon's research and manufacturing capabilities with Pfizer's global marketing prowess Global agreement for commercialization of Biocon's biosimilar versions of Insulin & Insulin Analogs: rh- Insulin, Glargine, A
Slide 18: Diabetes Prevalence
Diabetes Prevalence (% of population) Diabetics (absolute nos. ) Source: International Diabetes Atlas 2011 18
Slide 19: Biosimilars: Global Opportunity
BIOSIMILARS: GLOBAL OPPORTUNITY Total 2010 Insulin Market USD ~15 Bn Total 2010 Biologics Market* USD ~138 Bn rh insulin Biocon’ s 21% Target Opportunity Lispro 14% Glargine 32% detemir 8% Aspart glulisine 2% 23% Expected to be USD ~20 Bn in 2020 Expected to be USD ~200 Bn in 2015 * Biologics Includ
Slide 20: Biosimilars Commercialization Partnership: Mylan
BIOSIMILARS COMMERCIALIZATION PARTNERSHIP: MYLAN Monoclonal Antibodies (MAbs) Combines Biocon's R&D and manufacturing prowess of novel biologics/ bio-generics with Mylan’s regulatory & commercialization capabilities in the US and Europe Market size for product portfolio in 2010 : USD ~30 bn Exclusiv
Slide 21: Research & Development
Research & Development
Slide 22: Research Partnerships: High Potential Product Pipeline
RESEARCH PARTNERSHIPS : HIGH POTENTIAL PRODUCT PIPELINE US IND filed by partner (Amylin) for AC165198 Several Bi-specific fusion proteins under development with IATRICa * Including molecules from collaborative programs 22
Slide 23: Anti-CD6 MAb: Itolizumab
ANTI-CD6 MAb: Itolizumab Drug Highlights Targets CD6 CD6 is a type 1 cell membrane glycoprotein belonging to the scavenger receptor cysteine-rich (SRCR) super family group B. CD6 is predominantly expressed by T cells & a B cell subset. CD6 binds ALCAM (activated leukocyte cell adhesion molecule) whi
Slide 24: TREAT PLAQ Study: Summary of Results
TREAT PLAQ STUDY: SUMMARY OF RESULTS# PRIMARY ENDPOINT Result* Statistically significant patient cohort with ≥ PASI 75 at 12 Weeks SECONDARY ENDPOINTS Significant Proportion of subjects achieving PASI 50 and PASI 90 Safety & Tolerability Improvement in PGA scores Considerable Proportion of s
Slide 25: TREAT PLAQ Study: Efficacy Results
TREAT PLAQ STUDY : EFFICACY RESULTS Representative patient samples from each arm. Week Baseline 12 Weeks 28 Weeks Trial Arm Induction Dose Arm Fixed Dose Arm Placebo Arm 25
Slide 26: TREAT PLAQ Study: Overall Conclusions
TREAT PLAQ STUDY: OVERALL CONCLUSIONS First in class therapy, with a novel MOA, novel target and an excellent safety profile Successfully achieved primary endpoint of PASI-75 at 12 weeks with continued improvement in efficacy over time Very low infection rates observed compared to reported rat
Slide 27: Oral Insulin IN-105
ORAL INSULIN IN-105 Drug Highlights Conjugated peptide Lower immunogenicity and mitogenicity. Comparable safety and good clearance profile. Metabolically equivalent. Monotherapy. Combination therapy with metformin, sulfonylurea, PPAR agonists, DPP4i. Pre-meal insulin in combination with basal insuli
Slide 28: IN-105 India Phase III Result Summary
IN-105 INDIA PHASE III RESULT SUMMARY SECONDARY END POINTS Efficacy – Secondary Endpoints Statistically significant reduction in PPG during STM Significant reduction in SMBG post prandial glucose excursion Safety – Secondary Endpoints No clinically significant hypoglycemia Very low immunogenic
Slide 29: Financial Highlights
FINANCIAL HIGHLIGHTS
Slide 30: Top Line & Bottom Line
TOP LINE# & BOTTOM LINE# INR crore / USD mn FY08 FY09 FY10 FY11 Revenue 1090 273 1194 260 1493 318 1834 402 EBITDA 335 83 372 81 455 97 574 126 Net profit 225 56 238 52 273 58 340 74 9M FY12 9M FY11 Revenue 1511 | 319 1355 | 297 EBIDTA 425 | 90 426 | 93 28% 31% PAT 241 | 51 246 | 54 16% 18% EPS 12 1
Slide 31: Thank You
Thank You